25 May 2017 (Thursday) - The Oncologist Newsletter

The Oncologist Newsletter arrived in my in-box today:

Featured Article First‐Line Palliative HER2‐Targeted Therapy in HER2‐Positive Metastatic Breast Cancer Is Less Effective After Previous Adjuvant Trastuzumab‐Based Therapy Hánah N. Rier et al. In this study, less clinical benefit of palliative trastuzumab‐based therapy was observed in patients relapsing after adjuvant trastuzumab compared with no adjuvant trastuzumab treatment. Subgroup analyses and multivariable analyses revealed that this was independent of possible confounding factors, including adjuvant taxane‐treatment. This might suggest a clinically meaningful impaired efficacy of trastuzumab after previous, in this case adjuvant, trastuzumab therapy. These results could have implications for treatment decision‐making after short progression‐free intervals on trastuzumab‐containing regimens in the palliative setting. In the News Is Cabozantinib a Standard of Care for Advanced RCC? Where Body Fat Is Carried Can Predict Cancer Risk European Oncology Nursing Society (EONS) launches their inaugural European Cancer Nursing Day

CME Activities Using Metaphors to Explain Molecular Testing to Cancer Patients The Use of Hyperbaric Oxygen for the Prevention and Management of Osteoradionecrosis of the Jaw: a Dana-Farber/Brigham and Women’s Cancer Center Multidisciplinary Guideline Coming Soon... Conference Perspectives: Lessons Learned Conference Perspectives: Lessons Learned is the new CME-certified companion to The Oncologist’s Conference Perspectives series of in-depth conference reporting. In Lessons Learned, leading faculty will provide case-based guidance for applying new research to clinical practice. Click for more information.

Clinical Trial Results A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate Cancer Lessons Learned > The combination of standard dose abiraterone acetate and BEZ235, a pan‐class I PI3K and mTORC1/2 inhibitor, was poorly tolerated in men with progressive mCRPC. > Although the clinical development of BEZ235 has been discontinued in prostate cancer, agents that more selectively target PI3K‐AKT‐mTOR signaling may have a more favorable therapeutic index and should continue to be explored. T-Cell Therapy: Current Applications and Future Directions From the most recent Chabner Colloquium and STO Annual Meeting Marcela V. Maus, MD, PhD, Massachusetts General Hospital Cancer Center, Harvard Medical School discussed the components and technologies used in making a T-cell product, some of the factors considered to be important for efficacy, and recent results in hematologic malignancies and some solid tumors. Watch Now >